Pathogenesis and therapy of focal segmental glomerulosclerosis: an update

Springer Science and Business Media LLC - Tập 26 - Trang 1001-1015 - 2011
Rasheed Gbadegesin1, Peter Lavin2, John Foreman1, Michelle Winn2
1Department of Pediatrics, Duke University Medical Center, Durham, USA
2Department of Medicine, Duke University Medical Center, Durham, USA

Tóm tắt

Focal and segmental glomerulosclerosis (FSGS) is an important cause of steroid-resistant nephrotic syndrome in adults and children. It is responsible for 5–20% of all cases of end-stage kidney disease (ESKD) in the United States. The pathogenesis of FSGS has not been fully elucidated; however, data from molecular studies of familial cases in the last two decades suggest that FSGS is a defect of the podocyte. The therapeutic agents available for treatment of FSGS are not very effective and only a small percentage of affected individuals will achieve complete remission. Recent data from molecular biology and molecular genetics has provided insight into the mechanisms of action of old agents and also identification of other novel therapeutic targets. This review focuses on recent advances in the molecular pathogenesis of FSGS and currently available therapeutic agents as well as potential novel therapies.

Tài liệu tham khảo

Churg J, Habib R, White RH (1970) Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. Lancet 760:1299–1302

U.S. Renal Data System (2007) USRDS 2007 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD

White RH, Glasgow EF, Mills RJ (1970) Clinicopathological study of nephrotic syndrome in childhood. Lancet 1:1353–1359

Ballermann BJ, Stan RV (2007) Resolved: capillary endothelium is a major contributor to the glomerular filtration barrier. J Am Soc Nephrol 18:2432–2438

Shalhoub RJ (1974) Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 2:556–560

Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC (2005) Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16:2941–2952

Winn MP (2008) 2007 Young Investigator Award: TRP’ing into a new era for glomerular disease. J Am Soc Nephrol 19:1071–1075

Eckel J, Mukerji N, Lavin P, Ferimazova N, Gbadegesin R, Damodaran T, Bowling B, Wu G, Homstad A, Barisoni L, Bartkowiak B, Winn M (2009) TRPC6 deficiency does not cause glomerulosclerosis. J Am Soc Nephrol 20:314A

Gbadegesin RA, Damodaran T, Homstad A, Bartkowiak B, Bowling B, Wu G, Lavin P, Eckel J, Mukerji N, Winn M (2009) TRPC6 gene dose ameliorates the course of puromycin induced kidney injury. J Am Soc Nephrol 20:318A

Mucha B, Ozaltin F, Hinkes BG, Hasselbacher K, Ruf RG, Schultheiss M, Hangan D, Hoskins BE, Everding AS, Bogdanovic R, Seeman T, Hoppe B, Hildebrandt F, Members of the APN Study Group (2006) Mutations in the Wilms' tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9. Pediatr Res 59:325–331

Wing MR, Bourdon DM, Harden TK (2003) PLC-epsilon: a shared effector protein in Ras-, Rho-, and G alpha beta gamma-mediated signaling. Mol Interv 3:273–280

Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS, Family Investigation of Nephropathy and Diabetes Research Group (2008) MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40:1185–1192

Franceschini N, Voruganti VS, Haack K, Almasy L, Laston S, Goring HH, Umans JG, Lee ET, Best LG, Fabsitz RR, MacCluer JW, Howard BV, North KE, Cole SA (2010) The association of the MYH9 gene and kidney outcomes in American Indians: the Strong Heart Family Study. Hum Genet 127:295–301

ISKDC (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13:159–165

Tune BM, Mendoza SA (1997) Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults. J Am Soc Nephrol 8:824–832

Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL (1999) A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 56:2220–2226

Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP (1998) Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 9:2055–2066

Penny MJ, Boyd RA, Hall BM (1998) Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 9:2272–2282

Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H (2010) Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS). II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 55:50–60

Peyser A, Machardy N, Tarapore F, Machardy J, Powell L, Gipson DS, Savin V, Pan C, Kump T, Vento S, Trachtman H (2010) Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS. III. Report of the FONT study group. BMC Nephrol 11:2

Joy MS, Gipson DS, Dike M, Powell L, Thompson A, Vento S, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H (2009) Phase I trial of rosiglitazone in FSGS. I. Report of the FONT Study Group. Clin J Am Soc Nephrol 4:39–47